← Back to Patent Explorer
US4170639A Expired / Lapsed US ⏱️ 0.0 years remaining

Antihemophilic factor concentrate and its production

Assignee: Oesterreichisches Institut fuer Haemoderivate
•
Filing: 1978-07-10
•
Granted: 1979-10-09
•
Expires: 1998-07-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Antihemophilic factor (AHF) concentrate having enhanced potency and solubility and its process of production are provided. The process includes the steps of removing unwanted protein from an aqueous extract of antihemophilic blood plasma cryoprecipitate by mixing the aqueous extract with aluminum hydroxide at an acid pH in the cold, adjusting the purified aqueous extract to an acid pH and freeze-drying the extract, optionally removing water from the extract just before freeze-drying.

Inventors

  • 👤 Daniel T. H. Liu
  • 👤 John F. Irwin
  • 👤 Rong-Chang Pai

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 15:52
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 98 words
Process for the production of antihemophilic factor concentrate in purified form having enhanced potency and solubility comprising the steps of (a) subjecting an aqueous extract of antihemophilic blood plasma cryoprecipitate to purification by mixing with an aluminum hydroxide adsorbent at an acid pH and precipitating unwanted protein in the cold, the pH conditions being such that unwanted protein is selectively removed by adsorption without substantial loss of antihemophilic factor potency from the aqueous extract, (b) constituting the purified aqueous extract with buffer and saline and adjusting to an acid pH, and (c) freeze-drying the thus adjusted aqueous extract.
Claim 2
Dependent Claim 98 words
Process for the production of antihemophilic factor concentrate in purified form having enhanced potency and solubility comprising the steps of (a) subjecting an aqueous extract of antihemophilic blood plasma cryoprecipitate to purification by mixing with an aluminum hydroxide adsorbent at an acid pH and precipitating unwanted protein in the cold, the pH conditions being such that unwanted protein is selectively removed by adsorption without substantial loss of antihemophilic factor potency from the aqueous extract, (b) constituting the purified aqueous extract with buffer and saline and adjusting to an acid pH, and (c) freeze-drying the thus adjusted aqueous extract.
Claim 3
Dependent Claim 20 words
Process according to claim 1, where the purification is done in the pH range between about 6.55 to about 6.8.
Claim 4
Dependent Claim 22 words
Process according to claim 1, where the purified aqueous extract is adjusted to the pH range between about 6.55 and about 6.8.
Claim 5
Dependent Claim 21 words
Process according to claim 1, where the adjusted aqueous extract is concentrated by removal of water prior to the freeze-drying step.
Claim 6
Dependent Claim 17 words
Process according to claim 4, where the water is removed by subjecting the aqueous extract to ultrafiltration.
Claim 7
Dependent Claim 16 words
Process according to claim 5, where the water is removed by means of a semi-permeable membrane.
Claim 8
Dependent Claim 44 words
Process according to claim 1 where the purified aqueous extract is constituted with buffer and saline and is adjusted to the pH range between about 6.55 and about 6.8, and, prior to the freeze-drying step, the thus adjusted aqueous extract is concentrated by ultrafiltration.
Claim 9
Dependent Claim 10 words
Antihemophilic factor concentrate produced by the process of claim 1.
Claim 10
Dependent Claim 10 words
Antihemophilic factor concentrate produced by the process of claim 4.
Claim 11
Dependent Claim 10 words
Antihemophilic factor concentrated produced by the process of claim 5.

References Cited (Backward Citations)

US3652530A Cited
US3973002A Cited
US4093608A Cited
US4087415A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-10-08 1983-04-09 1983-10-09 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-10-08 1987-04-09 1987-10-09 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-10-08 1991-04-09 1991-10-09 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag